Table 2.
Summary of venetoclax-based combinations in AML
| Combination | Phase | Disease status | Patient number | CR/CRi rate, % | References |
|---|---|---|---|---|---|
| FLA-Ida | Retrospective | R/R AML | 13 | 69% | [9] |
| FLAG-ida | Ib/II |
ND AML R/R AML |
27 35 |
89% in ND AML 66% in R/R AML |
[10, 11] |
| CAVEAT (5 + 2) | Ib | ND AML | 51 |
72% in all 97% in de novo AML 43% secondary AML |
[12] |
| DEC10 | II |
ND AML R/R AML |
70 55 |
86% in ND AML 42% in R/R AML |
[13] |
| CLIA | II | ND AML | 18 | 88% | [14] |
| CLAD/LDAC, alternating with AZA | II | ND AML | 48 | 94% | [15] |
| CPX-351 | II |
R/R AML ND AML |
17 1 |
37% | [16] |
| CPX-351 LIT | Ib | ND AML | 44 planned | NA | [17] |
| GO | Ib | R/R AML | 24 planned | NA | [18] |